Alkermes reports positive Phase 1b topline in adult ADHD
Alkermes said its Phase 1b proof-of-concept for ALKS 7290, an oral OX2R agonist, showed dose-dependent improvements on exploratory ADHD scales after 14 days and a favorable safety profile. A Phase 2 adult ADHD study is enrolling.
Alkermes reported positive topline Phase 1b results for ALKS 7290, an oral OX2R agonist, showing dose-dependent, clinically meaningful improvements on exploratory ADHD scales after 14 days and a favorable safety profile. Material DetailsContext by AI…